Idiopathic pulmonary fibrosis - a systematic review on methodology for the collection of epidemiological data

BMC Pulmonary Medicine

Marjukka Myllärniemi⁴  Riitta Kaarteenaho¹  Ulla Hodgson³  Eija-Riitta Salomaa²  Jaana Kaunisto² 

[1] Respiratory Research Unit and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland;Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland;Division of Pulmonary Medicine, Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland;Departement of Clinical Medicine, Division of Pulmonary Medicine, University of Helsinki, Biomedicum, PoBox 63, 00014, Helsinki C405b, Finland

关键词: Register;    Mortality;    Prevalence;    Incidence;    Interstitial lung disease;   

Others  :  1122288
DOI  :  10.1186/1471-2466-13-53

 received in 2013-03-06, accepted in 2013-08-14,  发布年份 2013

【 摘 要 】

Background

Recent studies suggest that the incidence of idiopathic pulmonary fibrosis (IPF) is rising. Accurate epidemiological data on IPF, however, are sparse and the results of previous studies are contradictory. This study was undertaken to gain insight into the various methods used in the epidemiological research of IPF, and to get accurate and comparable data on these different methodologies.

Methods

A systematic database search was performed in order to identify all epidemiological studies on IPF after the previous guidelines for diagnosis and treatment were published in 2000. Medline (via Pubmed), Science Sitation Index (via Web of Science) and Embase databases were searched for original epidemiological articles published in English in international peer-reviewed journals starting from 2001. After pre-screening and a full-text review, 13 articles were accepted for data abstraction.

Results

Three different methodologies of epidemiological studies were most commonly used, namely: 1) national registry databases, 2) questionnaire-based studies, and 3) analysis of the health care system’s own registry databases. The overall prevalence and incidence of IPF varied in these studies between 0.5–27.9/100,000 and 0.22–8.8/100,000, respectively. According to four studies the mortality and incidence of IPF are rising.

Conclusions

We conclude that there are numerous ways to execute epidemiological research in the field of IPF. This review offers the possibility to compare the different methodologies that have been used, and this information could form a basis for future studies investigating the prevalence and incidence of IPF.

【 授权许可】

   
2013 Kaunisto et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
• [2]Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, CAPACITY Study Group: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
• [3]Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T, Pirfenidone Clinical Study Group in Japan: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
• [4]Izumi S, Iikura M, Hirano S: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 30:367-870.
• [5]American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
• [6]American Thoracic Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165:277-304.
• [7]Guenther A: The European IPF Network: towards better care for a dreadful disease. Eur Respir J 2011, 37:747-748.
• [8]Macansch S, Glaspole I, Hopkins P, Moodley Y, Reynolds P, Walters H, Zappala C, Chapman S, Cooper W, Darbishire W, Ellis S, Corte TJ: The Australian Idiopathic Pulmonary Fibrosis Registry – A National Collaboration Provides Epidemiological Insights And Research Opportunities. Am J Respir Crit Care Med 2013, 187:A1457.
• [9]Thomeer MJ, Costabel U, Rizzato G, Poletti V, Demedts M: Comparison of registries on interstitial lung diseases in three European countries. Eur Respir J 2001, 18:114s-118s.
• [10]Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK: Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med 2012, 106:588-593.
• [11]Lederer DJ, Arcasoy SM, Barr RG, Wilt J, Bagiella E, D’Ovidio F, Sonett JR, Kawutt SM: Racial and ethnic disparities in idiopathic pulmonary fibrosis: a UNOS/OPTN database analysis. Am J Transplant 2006, 6:2436-2442.
• [12]Jeon K, Chung MP, Lee KS, Chung MJ, Han J, Koh W-J, Suh GY, Kim H, Kwon OJ: Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis. Respir Med 2006, 100:451-457.
• [13]Miyake Y, Sasaki S, Yokoyama T, Chida K, Azuma A, Suda T, Kudoh S, Sakamoto N, Okamoto K, Kobashi G, Washio M, Inaba Y, Tanaka H: Case–control study of medical history and idiopathic pulmonary fibrosis in Japan. Respirology 2005, 10:504-509.
• [14]Young LM, Hopkins R, Wilsher ML: Lower occurrence of idiopathic pulmonary fibrosis in Maori and Pacific Islanders. Respirology 2006, 11:467-470.
• [15]Olson AL, Swigris JJ, Raghu G, Brown KK: Seasonal Variotion. Mortality From Pulmonary Fibrosis Is Greatest in the Winter. Chest 2009, 136:16-22.
• [16]Agostini C, Albera C, Bariffi F, De Palma M, Harari S, Lusuardi M, Pesci A, Poletti V, Richledi L, Riazzato G, Rossi A, Schiavina M, Semenzato G, Tinelli C: First report of the Italian register for diffuse infiltrative lung disorders (RIPID). Monaldi Arch Chest Dis 2001, 56:364-368.
• [17]Sen T, Udwadia ZF: Retrospective Study of Interstitial Lung Disease in a Tertiary Care Centre in India. Indian J Chest Dis Allied Sci 2010, 52:207-211.
• [18]Thomeer M, Demedts M, Vandeurzen K: Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg 2001, 56:163-172.
• [19]Tinelli C, De Silvestri A, Richeldi L, Tiberio O: The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis 2005, 22:S4-S8.
• [20]Xaubet A, Ancochea J, Morell F, Spanish Group on Interstitial Lung Diseases, SEPAR, et al.: Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:64-70.
• [21]Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, Latsi P, Polychronopoulos V, Birba G, Ch L, Bouros D: Epidemiology of interstitial lung diseases in Greece. Respir Med 2009, 103:1122-1229.
• [22]Hodgson U, Laitinen T, Tukiainen P: Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002, 57:338-342.
• [23]Von Plessen C, Grinde Ø, Gulsvik A: Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003, 97:428-435.
• [24]Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ: Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006, 61:980-985.
• [25]Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:810-816.
• [26]Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson G, Brown KK: Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007, 176:277-284.
• [27]Ohno S, Nakaya T, Bando M, Sugiyma Y: Idiopathic pulmonary fibrosis – results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008, 13:926-928.
• [28]Fernández Pérez ER, Daniels CE, Schroede DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ruy JH: Incidence, Prevalence and Clinical Course of Idiopathic Pulmonary Fibrosis. Chest 2010, 137:129-137.
• [29]Navaratnam V, Fleming KM, West J, Smith CJP, Jenkins RG, Fogarty A, Hubbard RB: The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011, 66:462-467.
• [30]Lai CC, Wang C-Y, Lu H-M, Chen L, Teng N-C, Yan Y-H, Wang J-Y, Chang Y-T, Chao T-T, Lin H-I, Chen C-R, Yu C-J, Wang J-D: Idiopathic pulmonary fibrosis in Taiwan – A population-based study. Respir Med 2012, 106:1566-1574.
• [31]Liebow A: Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 1975, 8:1-31.
• [32]Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994, 150:967-972.
• [33]Turner-Warwick M, Burrows B, Johnson A: Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980, 35:171-180.
• [34]Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D: Characteristics and management of idiopathic pulmonary fibrosis: INSIGHT-IPF registry. Dtsch Med Wochenschr 2012, 137:2586-2588.
• [35]Liebow AA, Carrington CB: The interstitial pneumonias. In Frontiers in pulmonary radiology. Edited by Simon M, Potchen EJ, Lemay E. New York: Grune and Stratton; 1969:102-141.
• [36]Katzenstein AL, Fiorelli RF: Nonspesific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994, 18:136-147.
• [37]Katzenstein AL, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157:1301-1315.
• [38]Larsen BT, Colby TV: Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med 2012, 136:1234-1241.
• [39]Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, Collard HR: Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2012. (published online before print)
• [40]Macansh S, Glaspole I, Goh N, Hopkins P, Moodley Y, Reynolds P, Walters H, Wood-Baker R, Zappala C, Chapman S, Cooper W, Darbishire W, Ellis S, Mahar A, Chaplin H, Fuller J, Mcalister M, Stevens E, Symons K, Webster S, Corte TJ: The australian idiopathic pulmonary fibrosis registry: a national collaboration. Respirology 2013, 18:72.
• [41]Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D: Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012, 21:355-361.